CytomX Therapeutics Inc

6C1

Company Profile

  • Business description

    CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

  • Contact

    151 Oyster Point Boulevard
    Suite 400
    South San FranciscoCA94080
    USA

    T: +1 650 515-3185

    E: [email protected]

    https://www.cytomx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    69

Stocks News & Analysis

stocks

OpenAI is going public as the worst value among its peers

Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks

Wide moat healthcare leader remains undervalued

ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks

This US AI winner has been unstoppable. Is it time to sell?

Astonishing results have driven this AI stock into significantly overvalued territory.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,855.9079.60-0.89%
CAC 408,218.2426.05-0.32%
DAX 4024,759.05185.90-0.75%
Dow JONES (US)50,866.78695.15-1.35%
FTSE 10010,368.057.730.07%
HKSE24,961.95291.45-1.15%
NASDAQ25,709.431,121.53-4.18%
Nikkei 22566,588.12882.57-1.31%
NZX 50 Index13,161.9760.360.46%
S&P 5007,383.74200.57-2.64%
S&P/ASX 2008,625.1080.00-0.92%
SSE Composite Index4,027.7430.04-0.74%

Market Movers